<DOC>
	<DOCNO>NCT00640588</DOCNO>
	<brief_summary>This study explore HBV kinetics CHB patient first 24 week treatment telbivudine</brief_summary>
	<brief_title>Prospective Exploratory Study Describe Hepatitis B Virus ( HBV ) Kinetics During Treatment With Telbivudine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Male female , least 18 year age . Documented compensated HBeAg negative CHB define baseline HBV serology , DNA ALT criterion . Coinfection HCV , HDV , HIV . Prior therapy nucleos ( ) ides NA√èVE patient prior treatment lamivudine patient suboptimal response adefovir . History hepatic decompensation History malignancy Patient one additional know primary secondary cause liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis B , chronic</keyword>
	<keyword>Viral kinetics</keyword>
	<keyword>Telbivudine</keyword>
	<keyword>Adefovir</keyword>
	<keyword>Compliance</keyword>
</DOC>